Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia
- Conditions
- Graft Versus Host DiseaseAplastic Anemia
- First Posted Date
- 2001-06-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Northwestern Memorial Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT00017654
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis
- Conditions
- Systemic Sclerosis
- First Posted Date
- 2001-05-07
- Last Posted Date
- 2008-09-03
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT00016458
- Locations
- 🇺🇸
University of Colorado Cancer Center, Denver, Colorado, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2001-04-11
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT00014755
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸University of Colorado Cancer Center, Denver, Colorado, United States
Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome
- Conditions
- Systemic Lupus ErythematosusAntiphospholipid Antibody Syndrome
- First Posted Date
- 2001-02-02
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 35
- Registration Number
- NCT00010400
- Locations
- 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus
- Conditions
- Pemphigus
- First Posted Date
- 2001-02-02
- Last Posted Date
- 2008-10-02
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 35
- Registration Number
- NCT00010413
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
- Conditions
- Anemia, Hemolytic, AutoimmuneFelty SyndromePurpura, ThrombocytopenicAutoimmune Diseases
- First Posted Date
- 2001-02-02
- Last Posted Date
- 2008-09-10
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 32
- Registration Number
- NCT00010387
- Locations
- 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
Permeability Factor in Focal Segmental Glomerulosclerosis
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- Procedure: Plasma exchangeDrug: Cyclophosphamide
- First Posted Date
- 2000-12-25
- Last Posted Date
- 2016-02-10
- Lead Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Target Recruit Count
- 15
- Registration Number
- NCT00007475
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Myeloma Immunoglobulin Idiotype VaccineDrug: BortezomibDrug: CyclophosphamideBiological: GMCSF (granulocyte macrophage colony stimulating factor)Drug: CyclosporineDrug: Doxorubicin hydrochlorideDrug: EtoposideDrug: Fludarabine phosphateDrug: PrednisoneDrug: Vincristine SulfateDrug: MethotrexateBiological: GCSF (granulocyte colony stimulating factor)
- First Posted Date
- 2000-08-24
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00006184
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
- Conditions
- Purpura, Schoenlein-HenochGraft Versus Host DiseaseAnemia, Hemolytic, AutoimmuneRheumatoid ArthritisChurg-Strauss SyndromeHypersensitivity VasculitisWegener's GranulomatosisSystemic Lupus ErythematosusGiant Cell ArteritisPure Red Cell Aplasia
- First Posted Date
- 2000-07-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Fairview University Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT00006055
- Locations
- 🇺🇸
Fairview University Medical Center, Minneapolis, Minnesota, United States
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
- Conditions
- Chediak-Higashi SyndromeGraft Versus Host DiseaseX-Linked Lymphoproliferative SyndromeFamilial Erythrophagocytic LymphohistiocytosisHemophagocytic LymphohistiocytosisVirus-Associated Hemophagocytic Syndrome
- First Posted Date
- 2000-07-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Fairview University Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00006056
- Locations
- 🇺🇸
Fairview University Medical Center, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.